Pediatric embryonal brain tumors in the molecular era

References

• SEER Cancer Statistics Review 1975–2015. Table 29.1 [Internet]. 2019. Available from: https://seer.cancer.gov/csr/1975_2015/browse_csr.php.
   Google Scholar
• McKean-Cowdin R, Razavi P, Barrington-Trimis J, et al. Trends in childhood brain tumor incidence, 1973–2009. J Neurooncol. 2013 Nov;115(2):153–160. PubMed PMID: 23925828; PubMed Central PMCID: PMCPMC4056769.
   PubMed Web of Science ®Google Scholar
• Smoll NR, Drummond KJ. The incidence of medulloblastomas and primitive neurectodermal tumours in adults and children. J Clin Neurosci. 2012;19(11):1541–1544.
   PubMed Web of Science ®Google Scholar
• Zhang AS, Ostrom QT, Kruchko C, et al. Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010. Neuro Oncol. 2017 May 1;19(5):726–735. PubMed PMID: 28039365; PubMed Central PMCID: PMCPMC5464453.
   PubMed Web of Science ®Google Scholar
• Louis DN. International Agency for Research on Cancer. Revised 4th ed. Pages 176, 184, 201, 208, 209. Lyon:International Agency For Research On Cancer; 2016. (World Health Organization classification of tumours).
   Google Scholar
• Sin-Chan P, Li BK, Ho B, et al. Molecular Classification and Management of Rare Pediatric Embryonal Brain Tumors. Curr Oncol Rep. 2018 Jul 11;20(9):69. PubMed PMID: 29995179.
   PubMed Web of Science ®Google Scholar
• Versteege I, Sevenet N, Lange J, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature. 1998 Jul 9;394(6689):203–206. PubMed PMID: 9671307.
   PubMed Web of Science ®Google Scholar
• Gonzales M. The 2000 World Health Organization classification of tumours of the nervous system. J Clin Neurosci. 2001 Jan;8(1):1–3. PubMed PMID: 11148073
   PubMed Web of Science ®Google Scholar
• Li M, Lee KF, Lu Y, et al. Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell. 2009 Dec 8;16(6):533–546. PubMed PMID: 19962671; PubMed Central PMCID: PMCPMC3431561.
   PubMed Web of Science ®Google Scholar
• Hilden JM, Meerbaum S, Burger P, et al. Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry. J Clin Oncol. 2004 Jul 15;22(14):2877–2884. PubMed PMID: 15254056.
   PubMed Web of Science ®Google Scholar
• Ramaswamy V, Remke M, Bouffet E, et al. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol. 2016 Jun;131(6):821–831. PubMed PMID: 27040285; PubMed Central PMCID: PMCPMC4867119. DOI:10.1007/s00401-016-1569-6
   PubMed Web of Science ®Google Scholar
• Ramaswamy V, Taylor MD. Medulloblastoma: from myth to molecular. J Clin Oncol. 2017 Jul 20;35(21):2355–2363. PubMed PMID: 28640708.
   PubMed Web of Science ®Google Scholar
• Rorke LB, Packer RJ, Biegel JA. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. J Neurosurg. 1996 Jul;85(1):56–65. PubMed PMID: 8683283; eng
   PubMed Web of Science ®Google Scholar
• Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002 Jan;415(6870):436–442. PubMed PMID: 11807556; eng.
   PubMed Web of Science ®Google Scholar
• Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2011 Apr 10;29(11):1408–1414. PubMed PMID: 20823417; PubMed Central PMCID: PMCPMC4874239.
   PubMed Web of Science ®Google Scholar
• Kool M, Korshunov A, Remke M, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 2012 Apr;123(4):473–484. PubMed PMID: 22358457; PubMed Central PMCID: PMCPMC3306778.
   PubMed Web of Science ®Google Scholar
• Northcott PA, Jones DT, Kool M, et al. Medulloblastomics: the end of the beginning. Nat Rev Cancer. 2012 Dec;12(12):818–834. PubMed PMID: 23175120; PubMed Central PMCID: PMCPMC3889646.
   PubMed Web of Science ®Google Scholar
• Batora NV, Sturm D, Jones DT, et al. Transitioning from genotypes to epigenotypes: why the time has come for medulloblastoma epigenomics. Neuroscience. 2014 Apr;4(264):171–185. PubMed PMID: 23876321.
   PubMed Web of Science ®Google Scholar
• Archer TC, Ehrenberger T, Mundt F, et al. Proteomics, post-translational modifications, and integrative analyses reveal molecular heterogeneity within medulloblastoma subgroups. Cancer Cell. 2018 Sep 10;34(3):396–410 e8. PubMed PMID: 30205044.
   PubMed Web of Science ®Google Scholar
• Forget A, Martignetti L, Puget S, et al. Aberrant ERBB4-SRC signaling as a hallmark of Group 4 medulloblastoma revealed by integrative phosphoproteomic profiling. Cancer Cell. 2018 Sep 10;34(3):379–395 e7. PubMed PMID: 30205043.
   PubMed Web of Science ®Google Scholar
• Gottardo NG, Hansford JR, McGlade JP, et al. Medulloblastoma down under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathol. 2014 Feb;127(2):189–201. PubMed PMID: 24264598; PubMed Central PMCID: PMCPMC3895219.
   PubMed Web of Science ®Google Scholar
• Northcott PA, Shih DJ, Remke M, et al. Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol. 2012 Apr;123(4):615–626. PubMed PMID: 22057785; PubMed Central PMCID: PMCPMC3306784.
   PubMed Web of Science ®Google Scholar
• Leal LF, Evangelista AF, de Paula FE, et al. Reproducibility of the NanoString 22-gene molecular subgroup assay for improved prognostic prediction of medulloblastoma. Neuropathology. 2018 Oct;38(5):475–483. PubMed PMID: 30155928.
   PubMed Web of Science ®Google Scholar
• Cavalli FMG, Remke M, Rampasek L, et al. Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell. 2017 Jun 12;31(6):737–754 e6. PubMed PMID: 28609654; PubMed Central PMCID: PMCPMC6163053.
   PubMed Web of Science ®Google Scholar
• Northcott PA, Buchhalter I, Morrissy AS, et al. The whole-genome landscape of medulloblastoma subtypes. Nature. 2017 Jul 19;547(7663):311–317. PubMed PMID: 28726821; PubMed Central PMCID: PMCPMC5905700.
   PubMed Web of Science ®Google Scholar
• Schwalbe EC, Lindsey JC, Nakjang S, et al. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. Lancet Oncol. 2017 Jul;18(7):958–971. PubMed PMID: 28545823; PubMed Central PMCID: PMCPMC5489698.
   PubMed Web of Science ®Google Scholar
• Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol. 1999 Mar;17(3):832–845. PubMed PMID: 10071274.
   PubMed Web of Science ®Google Scholar
• Giangaspero F, Wellek S, Masuoka J, et al. Stratification of medulloblastoma on the basis of histopathological grading. Acta Neuropathol. 2006 Jul;112(1):5–12. PubMed PMID: 16685513.
   PubMed Web of Science ®Google Scholar
• Nageswara Rao AA, Wallace DJ, Billups C, et al. Cumulative cisplatin dose is not associated with event-free or overall survival in children with newly diagnosed average-risk medulloblastoma treated with cisplatin based adjuvant chemotherapy: report from the Children’s Oncology Group. Pediatr Blood Cancer. 2014 Jan;61(1):102–106. PubMed PMID: 23956184; PubMed Central PMCID: PMCPMC4591537.
   PubMed Web of Science ®Google Scholar
• Packer RJ, Goldwein J, Nicholson HS, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children’s Cancer Group Study. J Clin Oncol. 1999 Jul;17(7):2127–2136. PubMed PMID: 10561268.
   PubMed Web of Science ®Google Scholar
• Bailey CC, Gnekow A, Wellek S, et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Med Pediatr Oncol. 1995 Sep;25(3):166–178. PubMed PMID: 7623725.
   PubMedGoogle Scholar
• Packer RJ, Sutton LN, Elterman R, et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg. 1994 Nov;81(5):690–698. PubMed PMID: 7931615.
   PubMed Web of Science ®Google Scholar
• Geyer JR, Sposto R, Jennings M, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children’s Cancer Group. J Clin Oncol. 2005 Oct 20;23(30):7621–7631. PubMed PMID: 16234523.
   PubMed Web of Science ®Google Scholar
• Grill J, Sainte-Rose C, Jouvet A, et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol. 2005 Aug;6(8):573–580. PubMed PMID: 16054568.
   PubMed Web of Science ®Google Scholar
• Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med. 2005 Mar 10;352(10):978–986. PubMed PMID: 15758008.
   PubMed Web of Science ®Google Scholar
• von Bueren AO, von Hoff K, Pietsch T, et al. Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology. Neuro Oncol. 2011 Jun;13(6):669–679. PubMed PMID: 21636711; PubMed Central PMCID: PMCPMC3107096.
   PubMed Web of Science ®Google Scholar
• Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med. 1993 Jun 17;328(24):1725–1731. PubMed PMID: 8388548.
   PubMed Web of Science ®Google Scholar
• Dhall G, Grodman H, Ji L, et al. Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the “Head Start” I and II protocols. Pediatr Blood Cancer. 2008 Jun;50(6):1169–1175. PubMed PMID: 18293379.
   PubMed Web of Science ®Google Scholar
• Cohen BH, Geyer JR, Miller DC, et al. Pilot study of intensive chemotherapy with peripheral hematopoietic cell support for children less than 3 years of age with malignant brain tumors, the CCG-99703 Phase I/II Study. A report from the Children’s Oncology Group. Pediatr Neurol. 2015 Jul;53(1):31–46. PubMed PMID: 26092413; PubMed Central PMCID: PMCPMC5166616.
   PubMed Web of Science ®Google Scholar
• Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006 Oct;7(10):813–820. PubMed PMID: 17012043.
   PubMed Web of Science ®Google Scholar
• Ramaswamy V, Remke M, Adamski J, et al. Medulloblastoma subgroup-specific outcomes in irradiated children: who are the true high-risk patients? Neuro Oncol. 2016 Feb;18(2):291–297. PubMed PMID: 25605817; PubMed Central PMCID: PMCPMC4724171.
   PubMed Web of Science ®Google Scholar
• Gibson P, Tong Y, Robinson G, et al. Subtypes of medulloblastoma have distinct developmental origins. Nature. 2010 Dec 23;468(7327):1095–1099. PubMed PMID: 21150899; PubMed Central PMCID: PMCPMC3059767.
   PubMed Web of Science ®Google Scholar
• Northcott PA, Lee C, Zichner T, et al. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature. 2014 Jul 24;511(7510):428–434. PubMed PMID: 25043047; PubMed Central PMCID: PMCPMC4201514.
   PubMed Web of Science ®Google Scholar
• Zhukova N, Ramaswamy V, Remke M, et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol. 2013 Aug 10;31(23):2927–2935. PubMed PMID: 23835706; PubMed Central PMCID: PMCPMC4878050.
   PubMed Web of Science ®Google Scholar
• Rausch T, Jones DT, Zapatka M, et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell. 2012 Jan 20;148(1–2):59–71. PubMed PMID: 22265402; PubMed Central PMCID: PMCPMC3332216.
   PubMed Web of Science ®Google Scholar
• Kool M, Jones DT, Jager N, et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell. 2014 Mar 17;25(3):393–405. PubMed PMID: 24651015; PubMed Central PMCID: PMCPMC4493053.
   PubMed Web of Science ®Google Scholar
• Snuderl M, Triscott J, Northcott PA, et al. Deep sequencing identifies IDH1 R132S mutation in adult medulloblastoma. J Clin Oncol. 2015 Feb 20;33(6):e27–31. PubMed PMID: 24616312; PubMed Central PMCID: PMCPMC4517370.
   PubMed Web of Science ®Google Scholar
• Remke M, Ramaswamy V, Peacock J, et al. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol. 2013 Dec;126(6):917–929. PubMed PMID: 24174164; PubMed Central PMCID: PMCPMC3830749.
   PubMed Web of Science ®Google Scholar
• Li Y, Song Q, Day BW. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis. Acta Neuropathol Commun. 2019 Jul 30;7(1):123. PubMed PMID: 31362788; PubMed Central PMCID: PMCPMC6668073.
   PubMedGoogle Scholar
• Kieran MW, Chisholm J, Casanova M, et al. Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma. Neuro Oncol. 2017 Oct 19;19(11):1542–1552. PubMed PMID: 28605510; PubMed Central PMCID: PMCPMC5737275. DOI:10.1093/neuonc/nox109
   PubMed Web of Science ®Google Scholar
• Bandopadhayay P, Bergthold G, Nguyen B, et al. BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res. 2014 Feb 15;20(4):912–925. PubMed PMID: 24297863; PubMed Central PMCID: PMCPMC4198154.
   PubMed Web of Science ®Google Scholar
• Bandopadhayay P, Piccioni F, O’Rourke R, et al. Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. Nat Commun. 2019 Jun 3;10(1):2400. PubMed PMID: 31160565; PubMed Central PMCID: PMCPMC6546744.
   PubMedGoogle Scholar
• Pietsch T, Schmidt R, Remke M, et al. Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. Acta Neuropathol. 2014 Jul;128(1):137–149. PubMed PMID: 24791927; PubMed Central PMCID: PMCPMC4059991.
   PubMed Web of Science ®Google Scholar
• von Bueren AO, Kortmann RD, von Hoff K, et al. Treatment of children and adolescents with metastatic medulloblastoma and prognostic relevance of clinical and biologic parameters. J Clin Oncol. 2016 Dec;34(34):4151–4160. PubMed PMID: 27863192.
   PubMed Web of Science ®Google Scholar
• Lafay-Cousin L, Smith A, Chi SN, et al. Clinical, Pathological, and Molecular Characterization of Infant Medulloblastomas Treated with Sequential High-Dose Chemotherapy. Pediatr Blood Cancer. 2016 Sep;63(9):1527–1534. PubMed PMID: 27145464; PubMed Central PMCID: PMCPMC5031363.
   PubMed Web of Science ®Google Scholar
• Morfouace M, Shelat A, Jacus M, et al. Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma. Cancer Cell. 2014 Apr 14;25(4):516–529. PubMed PMID: 24684846; PubMed Central PMCID: PMCPMC3994669.
   PubMed Web of Science ®Google Scholar
• Northcott PA, Shih DJ, Peacock J, et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature. 2012 Aug 2;488(7409):49–56. PubMed PMID: 22832581; PubMed Central PMCID: PMCPMC3683624.
   PubMed Web of Science ®Google Scholar
• Ramaswamy V, Remke M, Shih D, et al. Duration of the pre-diagnostic interval in medulloblastoma is subgroup dependent. Pediatr Blood Cancer. 2014 Jul;61(7):1190–1194. PubMed PMID: 24616042.
   PubMed Web of Science ®Google Scholar
• Shih DJ, Northcott PA, Remke M, et al. Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol. 2014 Mar 20;32(9):886–896. PubMed PMID: 24493713; PubMed Central PMCID: PMCPMC3948094.
   PubMed Web of Science ®Google Scholar
• Ellison DW, Dalton J, Kocak M, et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol. 2011 Mar;121(3):381–396. PubMed PMID: 21267586; PubMed Central PMCID: PMCPMC3519926.
   PubMed Web of Science ®Google Scholar
• Cho YJ, Tsherniak A, Tamayo P, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2011 Apr 10;29(11):1424–1430. PubMed PMID: 21098324; PubMed Central PMCID: PMCPMC3082983.
   PubMed Web of Science ®Google Scholar
• Korshunov A, Remke M, Kool M, et al. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. Acta Neuropathol. 2012 Apr;123(4):515–527. PubMed PMID: 22160402.
   PubMed Web of Science ®Google Scholar
• Rahmann EP, Gilbertson RJ. Multiomic Medulloblastomas. Cancer Cell. 2018 Sep 10;34(3):351–353. PubMed PMID: 30205039.
   PubMed Web of Science ®Google Scholar
• Biegel JA, Zhou JY, Rorke LB, et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res. 1999 Jan 1;59(1):74–79. PubMed PMID: 9892189.
   PubMed Web of Science ®Google Scholar
• Biegel JA. Molecular genetics of atypical teratoid/rhabdoid tumor. Neurosurg Focus. 2006 Jan 15;20(1):E11. PubMed PMID: 16459991.
   PubMedGoogle Scholar
• Hasselblatt M, Gesk S, Oyen F, et al. Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid/rhabdoid tumor showing retained SMARCB1 (INI1) expression. Am J Surg Pathol. 2011 Jun;35(6):933–935. PubMed PMID: 21566516.
   PubMed Web of Science ®Google Scholar
• Bikowska B, Grajkowska W, Jozwiak J. Atypical teratoid/rhabdoid tumor: short clinical description and insight into possible mechanism of the disease. Eur J Neurol. 2011 Jun;18(6):813–818. PubMed PMID: 21159066.
   PubMed Web of Science ®Google Scholar
• Burger PC, Yu IT, Tihan T, et al. Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study. Am J Surg Pathol. 1998 Sep;22(9):1083–1092. PubMed PMID: 9737241.
   PubMed Web of Science ®Google Scholar
• Fruhwald MC, Biegel JA, Bourdeaut F, et al. Atypical teratoid/rhabdoid tumors-current concepts, advances in biology, and potential future therapies. Neuro Oncol. 2016 Jun;18(6):764–778. PubMed PMID: 26755072; PubMed Central PMCID: PMCPMC4864253.
   PubMed Web of Science ®Google Scholar
• Fonseca A, Huang A Unpublished work. 2019.
   Google Scholar
• Athale UH, Duckworth J, Odame I, et al. Childhood atypical teratoid rhabdoid tumor of the central nervous system: a meta-analysis of observational studies. J Pediatr Hematol Oncol. 2009 Sep;31(9):651–663. PubMed PMID: 19707161.
   PubMed Web of Science ®Google Scholar
• Picard D, Miller S, Hawkins CE, et al. Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis. Lancet Oncol. 2012 Aug;13(8):838–848. PubMed PMID: 22691720; PubMed Central PMCID: PMC3615440.
   PubMed Web of Science ®Google Scholar
• Tekautz TM, Fuller CE, Blaney S, et al. Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol. 2005 Mar 1;23(7):1491–1499. PubMed PMID: 15735125.
   PubMed Web of Science ®Google Scholar
• Hasselblatt M, Nagel I, Oyen F, et al. SMARCA4-mutated atypical teratoid/rhabdoid tumors are associated with inherited germline alterations and poor prognosis. Acta Neuropathol. 2014 Sep;128(3):453–456. PubMed PMID: 25060813.
   PubMed Web of Science ®Google Scholar
• Buscariollo DL, Park HS, Roberts KB, et al. Survival outcomes in atypical teratoid rhabdoid tumor for patients undergoing radiotherapy in a Surveillance, Epidemiology, and End Results analysis. Cancer. 2012 Sep 1;118(17):4212–4219. PubMed PMID: 22213196.
   PubMed Web of Science ®Google Scholar
• Chi SN, Zimmerman MA, Yao X, et al. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol. 2009 Jan 20;27(3):385–389. PubMed PMID: 19064966; PubMed Central PMCID: PMCPMC2645855.
   PubMed Web of Science ®Google Scholar
• Dufour C, Beaugrand A, Le Deley MC, et al. Clinicopathologic prognostic factors in childhood atypical teratoid and rhabdoid tumor of the central nervous system: a multicenter study. Cancer. 2012 Aug 1;118(15):3812–3821. PubMed PMID: 22180295.
   PubMed Web of Science ®Google Scholar
• Fonseca A, Al-Karmi S, Vasiljevic A, et al. Rare embryonal brain tumours. In: editor, Gajjar A. Brain tumors in children. Cham: Springer; 2018:289–316.
   Google Scholar
• Pai Panandiker AS, Merchant TE, Beltran C, et al. Sequencing of local therapy affects the pattern of treatment failure and survival in children with atypical teratoid rhabdoid tumors of the central nervous system. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1756–1763. PubMed PMID: 21601374; PubMed Central PMCID: PMCPMC3530399.
   PubMed Web of Science ®Google Scholar
• von Hoff K, Hinkes B, Dannenmann-Stern E, et al. Frequency, risk-factors and survival of children with atypical teratoid rhabdoid tumors (AT/RT) of the CNS diagnosed between 1988 and 2004, and registered to the German HIT database. Pediatr Blood Cancer. 2011 Dec 1;57(6):978–985. PubMed PMID: 21796761.
   PubMed Web of Science ®Google Scholar
• Gardner SL, Asgharzadeh S, Green A, et al. Intensive induction chemotherapy followed by high dose chemotherapy with autologous hematopoietic progenitor cell rescue in young children newly diagnosed with central nervous system atypical teratoid rhabdoid tumors. Pediatr Blood Cancer. 2008 Aug;51(2):235–240. PubMed PMID: 18381756.
   PubMed Web of Science ®Google Scholar
• Benesch M, Bartelheim K, Fleischhack G, et al. High-dose chemotherapy (HDCT) with auto-SCT in children with atypical teratoid/rhabdoid tumors (AT/RT): a report from the European Rhabdoid Registry (EU-RHAB). Bone Marrow Transplant. 2014 Mar;49(3):370–375. PubMed PMID: 24419520.
   PubMed Web of Science ®Google Scholar
• Zaky W, Dhall G, Ji L, et al. Intensive induction chemotherapy followed by myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for young children newly-diagnosed with central nervous system atypical teratoid/rhabdoid tumors: the Head Start III experience. Pediatr Blood Cancer. 2014 Jan;61(1):95–101. PubMed PMID: 23934933.
   PubMed Web of Science ®Google Scholar
• Reddy A, Strother D, Judkins A, et al. At-09treatment of Atypical Teratoid Rhabdoid Tumors (Atrt) of the central nervous system with surgery, intensive chemotherapy, and 3-D conformal radiation (Acns0333). A Report from the Children’s Oncology Group. Neuro Oncol. 2016;18(\(suppl 3)):iii2.4–iii2.
   PubMedGoogle Scholar
• Hasselblatt M, Isken S, Linge A, et al. High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/ rhabdoid tumors. Genes Chromosomes Cancer. 2013 Feb;52(2):185–190. PubMed PMID: 23074045.
   PubMed Web of Science ®Google Scholar
• Johann PD, Erkek S, Zapatka M, et al. Atypical teratoid/rhabdoid tumors are comprised of three epigenetic subgroups with distinct enhancer landscapes. Cancer Cell. 2016 Mar 14;29(3):379–393. PubMed PMID: 26923874.
   PubMed Web of Science ®Google Scholar
• McKenna ES, Sansam CG, Cho YJ, et al. Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability. Mol Cell Biol. 2008 Oct;28(20):6223–6233. PubMed PMID: 18710953; PubMed Central PMCID: PMCPMC2577431.
   PubMed Web of Science ®Google Scholar
• Torchia J, Golbourn B, Feng S, et al. Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell. 2016 Dec 12;30(6):891–908. PubMed PMID: 27960086; PubMed Central PMCID: PMCPMC5500911.
   PubMed Web of Science ®Google Scholar
• Wilson BG, Wang X, Shen X, et al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell. 2010 Oct 19;18(4):316–328. PubMed PMID: 20951942; PubMed Central PMCID: PMCPMC2957473.
   PubMed Web of Science ®Google Scholar
• Birks DK, Donson AM, Patel PR, et al. High expression of BMP pathway genes distinguishes a subset of atypical teratoid/rhabdoid tumors associated with shorter survival. Neuro Oncol. 2011 Dec;13(12):1296–1307. PubMed PMID: 21946044; PubMed Central PMCID: PMCPMC3223096.
   PubMed Web of Science ®Google Scholar
• Eberhart CG, Brat DJ, Cohen KJ, et al. Pediatric neuroblastic brain tumors containing abundant neuropil and true rosettes. Pediatr Dev Pathol. 2000 Jul-Aug;3(4):346–352. PubMed PMID: 10890250.
   PubMed Web of Science ®Google Scholar
• Pfister S, Remke M, Castoldi M, et al. Novel genomic amplification targeting the microRNA cluster at 19q13.42 in a pediatric embryonal tumor with abundant neuropil and true rosettes. Acta Neuropathol. 2009 Apr;117(4):457–464. PubMed PMID: 19057917; eng.
   PubMed Web of Science ®Google Scholar
• Spence T, Sin-Chan P, Picard D, et al. CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathol. 2014 Aug;128(2):291–303. PubMed PMID: 24839957; PubMed Central PMCID: PMCPMC4159569. eng.
   PubMed Web of Science ®Google Scholar
• Korshunov A, Sturm D, Ryzhova M, et al. Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. Acta Neuropathol. 2014 Aug;128(2):279–289. PubMed PMID: 24337497; PubMed Central PMCID: PMCPMC4102829.
   PubMed Web of Science ®Google Scholar
• Kleinman CL, Gerges N, Papillon-Cavanagh S, et al. Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR. Nat Genet. 2014 Jan;46(1):39–44. PubMed PMID: 24316981; eng.
   PubMed Web of Science ®Google Scholar
• Sin-Chan P, Mumal I, Suwal T, et al. A C19MC-LIN28A-MYCN oncogenic circuit driven by hijacked super-enhancers is a distinct therapeutic vulnerability in ETMRs: A lethal brain tumor. Cancer Cell. 2019;36(1):51–67.e7.
   PubMed Web of Science ®Google Scholar
• Jouvet A, Vasiljevic A, Nakazato Y, et al. Tumours of the pineal region. In: Louis D, editor. WHO classification of tumours of the central nervous system. 4 ed. Lyon: International Agency for Research on Cancer; 2016. p. 170–182.
   Google Scholar
• Hwang EI, Kool M, Burger PC, et al. Extensive molecular and clinical heterogeneity in patients with histologically diagnosed CNS-PNET treated as a single entity: a report from the Children’s Oncology Group Randomized ACNS0332 Trial. J Clin Oncol. 2018 Oct 17:JCO2017764720. PubMed PMID: 30332335. DOI:10.1200/JCO.2017.76.4720
   PubMed Web of Science ®Google Scholar
• Chintagumpala M, Hassall T, Palmer S, et al. A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. Neuro Oncol. 2009 Feb;11(1):33–40. PubMed PMID: 18796696; PubMed Central PMCID: PMCPMC2718957. eng.
   PubMed Web of Science ®Google Scholar
• Gururangan S, McLaughlin C, Quinn J, et al. High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas. J Clin Oncol. 2003 Jun 1;21(11):2187–2191. PubMed PMID: 12775745.
   PubMed Web of Science ®Google Scholar
• Mynarek M, Pizer B, Dufour C, et al. Evaluation of age-dependent treatment strategies for children and young adults with pineoblastoma: analysis of pooled European Society for Paediatric Oncology (SIOP-E) and US Head Start data. Neuro Oncol. 2017 04;19(4):576–585. PubMed PMID: 28011926; PubMed Central PMCID: PMCPMC5464312. eng.
   PubMed Web of Science ®Google Scholar
• Friedrich C, von Bueren AO, von Hoff K, et al. Treatment of young children with CNS-primitive neuroectodermal tumors/pineoblastomas in the prospective multicenter trial HIT 2000 using different chemotherapy regimens and radiotherapy. Neuro Oncol. 2013 Feb;15(2):224–234. PubMed PMID: 23223339; PubMed Central PMCID: PMCPMC3548584. eng.
   PubMed Web of Science ®Google Scholar
• Jakacki RI, Burger PC, Kocak M, et al. Outcome and prognostic factors for children with supratentorial primitive neuroectodermal tumors treated with carboplatin during radiotherapy: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2015 May;62(5):776–783. PubMed PMID: 25704363; PubMed Central PMCID: PMCPMC4376578. eng.
   PubMed Web of Science ®Google Scholar
• Liu APY, Gudenas B, Lin T, et al. Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials. Acta Neuropathol. 2019 Dec 4. PubMed PMID: 31802236. DOI:10.1007/s00401-019-02106-9
   Web of Science ®Google Scholar
• Blach LE, McCormick B, Abramson DH, et al. Trilateral retinoblastoma–incidence and outcome: a decade of experience. Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):729–733. PubMed PMID: 8040018.
   PubMed Web of Science ®Google Scholar
• de Kock L, Sabbaghian N, Druker H, et al. Germ-line and somatic DICER1 mutations in pineoblastoma. Acta Neuropathol. 2014 Oct;128(4):583–595. PubMed PMID: 25022261; PubMed Central PMCID: PMCPMC4381868. eng.
   PubMed Web of Science ®Google Scholar
• Sabbaghian N, Hamel N, Srivastava A, et al. Germline DICER1 mutation and associated loss of heterozygosity in a pineoblastoma. J Med Genet. 2012 Jul;49(7):417–419. PubMed PMID: 22717647.
   PubMed Web of Science ®Google Scholar
• Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015 Jun;15(6):321–333. PubMed PMID: 25998712; PubMed Central PMCID: PMCPMC4859809
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Priest JR, Duchaine TF. DICER1: mutations, microRNAs and mechanisms. Nat Rev Cancer. 2014 Oct;14(10):662–672. PubMed PMID: 25176334
   PubMed Web of Science ®Google Scholar
• Snuderl M, Kannan K, Pfaff E, et al. Recurrent homozygous deletion of DROSHA and microduplication of PDE4DIP in pineoblastoma. Nat Commun. 2018 Jul 20;9(1):2868. PubMed PMID: 30030436.
   PubMedGoogle Scholar
• Miller S, Rogers HA, Lyon P, et al. Genome-wide molecular characterization of central nervous system primitive neuroectodermal tumor and pineoblastoma. Neuro Oncol. 2011 Aug;13(8):866–879. PubMed PMID: 21798848; PubMed Central PMCID: PMCPMC3145471. eng.
   PubMed Web of Science ®Google Scholar
• Brown AE, Leibundgut K, Niggli FK, et al. Cytogenetics of pineoblastoma: four new cases and a literature review. Cancer Genet Cytogenet. 2006 Oct 15;170(2):175–179. PubMed PMID: 17011992.
   PubMedGoogle Scholar
• Rickert CH, Simon R, Bergmann M, et al. Comparative genomic hybridization in pineal parenchymal tumors. Genes Chromosomes Cancer. 2001 Jan;30(1):99–104. PubMed PMID: 11107183; eng.
   PubMed Web of Science ®Google Scholar
• Russo C, Pellarin M, Tingby O, et al. Comparative genomic hybridization in patients with supratentorial and infratentorial primitive neuroectodermal tumors. Cancer. 1999 Jul;86(2):331–339. PubMed PMID: 10421270; eng.
   PubMed Web of Science ®Google Scholar
• Tsumanuma I, Sato M, Okazaki H, et al. The analysis of p53 tumor suppressor gene in pineal parenchymal tumors. Noshuyo Byori. 1995 Mar;12(1):39–43. PubMed PMID: 7795728; eng.
   PubMedGoogle Scholar
• Tsumanuma I, Tanaka R, Abe S, et al. Infrequent mutation of Waf1/p21 gene, a CDK inhibitor gene, in brain tumors. Neurol Med Chir (Tokyo). 1997 Feb;37(2):150–6; discussion 156–7. PubMed PMID: 9059037; eng.
   PubMedGoogle Scholar
• Fevre-Montange M, Champier J, Szathmari A, et al. Microarray analysis reveals differential gene expression patterns in tumors of the pineal region. J Neuropathol Exp Neurol. 2006 Jul;65(7):675–684. PubMed PMID: 16825954.
   PubMed Web of Science ®Google Scholar
• Li BK, Vasiljevic A, Dufour C, et al. Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. Acta Neuropathol. 2019 Dec 9. PubMed PMID: 31820118. DOI:10.1007/s00401-019-02111-y
   Google Scholar
• Pfaff E, Aichmuller C, Sill M, et al. Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations. Acta Neuropathol. 2019 Nov 25. PubMed PMID: 31768671. DOI:10.1007/s00401-019-02101-0
   PubMedGoogle Scholar
• Gerber NU, von Hoff K, Resch A, et al. Treatment of children with central nervous system primitive neuroectodermal tumors/pinealoblastomas in the prospective multicentric trial HIT 2000 using hyperfractionated radiation therapy followed by maintenance chemotherapy. Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):863–871. PubMed PMID: 24969797.
   PubMed Web of Science ®Google Scholar
• Choi SH, Kim SH, Shim KW, et al. Treatment outcome and prognostic molecular markers of supratentorial primitive neuroectodermal tumors. PLoS One. 2016;11(4):e0153443. PubMed PMID: 27074032; PubMed Central PMCID: PMCPMC4830607
   PubMed Web of Science ®Google Scholar
• Sturm D, Orr BA, Toprak UH, et al. New brain tumor entities emerge from molecular classification of CNS-PNETs [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Cell. 2016 Feb 25;164(5):1060–1072. PubMed PMID: 26919435.
   PubMed Web of Science ®Google Scholar
• Modzelewska K, Boer EF, Mosbruger TL, et al. MEK Inhibitors reverse growth of embryonal brain tumors derived from oligoneural precursor cells. Cell Rep. 2016 Oct 25;17(5):1255–1264. PubMed PMID: 27783941.
   PubMed Web of Science ®Google Scholar
• Ho B, Huang A. [Unpublished work]. Hospital for Sick Children. Toronto, ON, Canada; 2019.
   Google Scholar
• Ueno-Yokohata H, Okita H, Nakasato K, et al. Consistent in-frame internal tandem duplications of BCOR characterize clear cell sarcoma of the kidney. Nat Genet. 2015 Aug;47(8):861–863. PubMed PMID: 26098867.
   PubMed Web of Science ®Google Scholar
• Haidar A, Arekapudi S, DeMattia F, et al. High-grade undifferentiated small round cell sarcoma with t(4;19)(q35;q13.1) CIC-DUX4 fusion: emerging entities of soft tissue tumors with unique histopathologic features–a case report and literature review. Am J Case Rep. 2015 Feb 16;16:87–94. PubMed PMID: 25683183; PubMed Central PMCID: PMCPMC4338805. DOI:10.12659/AJCR.892551
   PubMed Web of Science ®Google Scholar
• Roy A, Kumar V, Zorman B, et al. Recurrent internal tandem duplications of BCOR in clear cell sarcoma of the kidney. Nat Commun. 2015 Nov;17(6):8891. PubMed PMID: 26573325; PubMed Central PMCID: PMCPMC4660214.
   PubMed Web of Science ®Google Scholar
• Ferris SP, Velazquez Vega J, Aboian M, et al. High-grade neuroepithelial tumor with BCOR exon 15 internal tandem duplication-a comprehensive clinical, radiographic, pathologic, and genomic analysis. Brain Pathol. 2019 May 18. PubMed PMID: 31104347. DOI:10.1111/bpa.12747
   Google Scholar
• Rare Brain Tumor Consortium. 2019 [cited 2019 Sept 30]. Available from: http://www.rarebraintumorconsortium.ca/
   Google Scholar
• Vladoiu MC, El-Hamamy I, Donovan LK, et al. Childhood cerebellar tumours mirror conserved fetal transcriptional programs. Nature. 2019 Aug;572(7767):67–73. PubMed PMID: 31043743; PubMed Central PMCID: PMCPMC6675628.
   PubMed Web of Science ®Google Scholar
• Zhang L, He X, Liu X, et al. Single-cell transcriptomics in medulloblastoma reveals tumor-initiating progenitors and oncogenic cascades during tumorigenesis and relapse. Cancer Cell. 2019 Sep 16;36(3):302–318 e7. PubMed PMID: 31474569; PubMed Central PMCID: PMCPMC6760242.
   PubMed Web of Science ®Google Scholar
• Hovestadt V, Smith KS, Bihannic L, et al. Resolving medulloblastoma cellular architecture by single-cell genomics. Nature. 2019 Aug;572(7767):74–79. PubMed PMID: 31341285; PubMed Central PMCID: PMCPMC6754173.
   PubMed Web of Science ®Google Scholar
• Tirosh I, Izar B, Prakadan SM, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016 Apr 8;352(6282):189–196. PubMed PMID: 27124452; PubMed Central PMCID: PMCPMC4944528.
   PubMed Web of Science ®Google Scholar
• Lavin Y, Kobayashi S, Leader A, et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell. 2017 May 4;169(4):750–765 e17. PubMed PMID: 28475900; PubMed Central PMCID: PMCPMC5737939.
   PubMed Web of Science ®Google Scholar
• Zheng C, Zheng L, Yoo JK, et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell. 2017 Jun 15;169(7):1342–1356 e16. PubMed PMID: 28622514.
   PubMed Web of Science ®Google Scholar